FCGR2B and rheumatoid arthritis: Co-engaging of the B-cell receptor complex together with FcγRIIb by this engineered antibody suppressed B-cell activation and function, including IgG secretion and IL-6 production (85–87), which therefore may be of therapeutic benefit in IgG-mediated autoimmune diseases such as RA and SLE.